Los Altos, California-based RenovoRx develops precision oncology therapies based on a local drug delivery platform. Closing this funding round extends the company’s cash runway as it conducts its pivotal TIGer-PaC Phase III clinical trial. It expects the funds to aid operations through 2024.
TIGer-PaC uses RenovoRx’s proprietary TAMP therapy platform to evaluate its first product candidate, the RenovoGem. RenovoGem, a novel oncology drug-device combination, is designed to treat locally advanced pancreatic cancer (LAPC). The study compares TAMP treatment to the current standard of care, systemic intravenous chemotherapy.
Get the full story at our sister site, Drug Delivery Business News.
